GENERALIZED ECZEMATOUS SKIN RASH POSSIBLY DUE TO HMG-COA REDUCTASE INHIBITORS

被引:46
|
作者
KRASOVEC, M
ELSNER, P
BURG, G
机构
[1] Department of Dermatology, University Hospital Zurich, CH-80?1 Zurich
关键词
HMG-COA REDUCTASE INHIBITORS; SIDE EFFECTS; SKIN RASH; EPIDERMAL LIPIDS;
D O I
10.1159/000247363
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
We report on 3 patients who developed a generalized eczematous skin rash under treatment with simvastatin and pravastatin for hypercholesterolemia. These drugs are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors and suppress cholesterol synthesis in the liver. Based on experimental data from the literature that showed eczematous changes in mice treated topically with the HMG-CoA reductase inhibitor lovastatin, we suspect that the rash observed in our patients may be a consequence of skin barrier dysfunction following inhibition of cholesterol biosynthesis.
引用
收藏
页码:248 / 252
页数:5
相关论文
共 50 条
  • [41] HMG-CoA reductase inhibitors as adjuvant treatment for hematologic malignancies: what is the current evidence?
    Bockorny, Bruno
    Dasanu, Constantin A.
    ANNALS OF HEMATOLOGY, 2015, 94 (01) : 1 - 12
  • [42] Polymyalgia, hypersensitivity pneumonitis and other reactions in patients receiving HMG-CoA reductase inhibitors
    Liebhaber, MI
    Wright, RS
    Gelberg, HJ
    Dyer, Z
    Kupperman, JL
    CHEST, 1999, 115 (03) : 886 - 889
  • [43] HMG-CoA reductase inhibitors as adjuvant treatment for hematologic malignancies: what is the current evidence?
    Bruno Bockorny
    Constantin A. Dasanu
    Annals of Hematology, 2015, 94 : 1 - 12
  • [44] Involvement of agmatine in antidepressant-like effect of HMG-CoA reductase inhibitors in mice
    Rahangdale, Sandip
    Fating, Rajshree
    Gajbhiye, Mona
    Kapse, Mona
    Inamdar, Nazma
    Kotagale, Nandkishor
    Umekar, Milind
    Taksande, Brijesh
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2021, 892
  • [45] Cataract and HMG-CoA reductase inhibitor: a case report
    Bousquet, E
    Amar, J
    Salvador, M
    Chamontin, B
    THERAPIE, 1998, 53 (05): : 505 - 507
  • [46] HMG-CoA reductase inhibitors and the attenuation of risk for disseminated intravascular coagulation in patients with sepsis
    Nicholas B. Alana
    William A. Ciurylo
    Natalie Hurlock
    Journal of Thrombosis and Thrombolysis, 2024, 57 : 260 - 268
  • [47] SYNTHESIS OF NOVEL HMG-COA REDUCTASE INHIBITORS .1. NAPHTHALENE ANALOGS OF MEVINOLIN
    NOVAK, L
    ROHALY, J
    POPPE, L
    HORNYANSZKY, G
    KOLONITS, P
    ZELEI, I
    FEHER, I
    FEKETE, J
    SZABO, E
    ZAHORSZKY, U
    JAVOR, A
    SZANTAY, C
    LIEBIGS ANNALEN DER CHEMIE, 1992, (02): : 145 - 157
  • [48] HMG-CoA reductase inhibitors (statins) and bone mineral density: A meta-analysis
    Liu, Jie
    Zhu, Li-Ping
    Yang, Xu-Li
    Huang, He-Lang
    Ye, Dong-Qing
    BONE, 2013, 54 (01) : 151 - 156
  • [49] Effect of HMG-CoA reductase inhibitors on plasma polyunsaturated fatty acid concentrations in patients with hyperlipidemia
    Nakamura, N
    Hamazaki, T
    Jokaji, H
    Minami, S
    Kobayashi, M
    INTERNATIONAL JOURNAL OF CLINICAL & LABORATORY RESEARCH, 1998, 28 (03) : 192 - 195
  • [50] Simvastatin and Other HMG-CoA Reductase Inhibitors on Brain Cholesterol Levels in Alzheimer's Disease
    Longenberger, Justin
    Shah, Zahoor A.
    CURRENT ALZHEIMER RESEARCH, 2011, 8 (04) : 434 - 442